Vikram Paradkar

No ORCID on file · 1 paper in corpus · active 2025
2025
A Phase III Randomized Controlled Trial Assessing the Safety and Immunogenicity of Biological E’s XBB 1.5 RBD Subunit COVID-19 Booster Vaccine in Individuals Aged 5 to 80 Years
·doi:10.1101/2025.06.16.25329675

Summary Background The SARS-CoV-2 virus continues to evolve with recent iterations such as the Omicron sub-variants having potential for increased transmissibility. Of particular interest, the XBB.1.5 variant has been shown to cause vaccine…